Ypsomed signs autoinjector supply deal with Novo Nordisk

The autoinjectors will be used to administer drugs for self-treatment in various metabolic indications, Ypsomed said, adding that the deal was expected to contribute to commercial sales starting from the 2025/26 financial year. Novo has been unable to keep pace with demand for its popular weight-loss drug Wegovy, which uses self-injection pens, in the five markets – the United States and four European countries – where it is available. Ypsomed said it would expand its manufacturing capacities over the coming years, with Novo Nordisk contributing a significant part of the investment for the additional production infrastructure.